Detection and Early Referral of Patients With Interstitial Lung Abnormalities: An Expert Survey Initiative.

[1]  I. Rosas,et al.  Subclinical interstitial lung disease: why you should care. , 2012, American journal of respiratory and critical care medicine.

[2]  R. Sussman,et al.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. , 2014, The New England journal of medicine.

[3]  D. Esser,et al.  Treatment patterns, resource use and costs of idiopathic pulmonary fibrosis in Spain – results of a Delphi Panel , 2016, BMC Pulmonary Medicine.

[4]  D. Lynch,et al.  Interstitial lung abnormalities in a CT lung cancer screening population: prevalence and progression rate. , 2013, Radiology.

[5]  Raúl San José Estépar,et al.  Development and Progression of Interstitial Lung Abnormalities in the Framingham Heart Study. , 2016, American journal of respiratory and critical care medicine.

[6]  Katherine P Andriole,et al.  Lung volumes and emphysema in smokers with interstitial lung abnormalities. , 2011, The New England journal of medicine.

[7]  G. Washko,et al.  Histopathology of Interstitial Lung Abnormalities in the Context of Lung Nodule Resections , 2017, American journal of respiratory and critical care medicine.

[8]  I. Rosas,et al.  Genetics and early detection in idiopathic pulmonary fibrosis. , 2014, American journal of respiratory and critical care medicine.

[9]  C. Thomson,et al.  American Thoracic Society/American Lung Association Lung Cancer Screening Implementation Guide. , 2018, American journal of respiratory and critical care medicine.

[10]  H. Collard,et al.  Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. , 2014, The New England journal of medicine.

[11]  Raúl San José Estépar,et al.  MUC5B promoter polymorphism and interstitial lung abnormalities. , 2013, The New England journal of medicine.

[12]  David J. Lederer,et al.  Barriers to timely diagnosis of interstitial lung disease in the real world: the INTENSITY survey , 2018, BMC Pulmonary Medicine.

[13]  Michael F. McNitt-Gray,et al.  ACR–STR Practice Parameter for the Performance and Reporting of Lung Cancer Screening Thoracic Computed Tomography (CT): 2014 (Resolution 4)* , 2014, Journal of thoracic imaging.

[14]  G. Washko,et al.  Imaging Patterns are Associated with Interstitial Lung Abnormality Progression and Mortality. , 2019, American journal of respiratory and critical care medicine.

[15]  J. W. Lee,et al.  Extensive phenotyping of individuals at risk for familial interstitial pneumonia reveals clues to the pathogenesis of interstitial lung disease. , 2015, American journal of respiratory and critical care medicine.

[16]  M. Kreuter,et al.  Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. , 2020, The Lancet. Respiratory medicine.

[17]  I. Annesi-Maesano,et al.  The Occupational Burden of Nonmalignant Respiratory Diseases. An Official American Thoracic Society and European Respiratory Society Statement , 2019, American journal of respiratory and critical care medicine.

[18]  Interstitial lung abnormalities and reduced exercise capacity. , 2012, American journal of respiratory and critical care medicine.

[19]  L. Wain,et al.  Overlap of Genetic Risk Between Interstitial Lung Abnormalities and Idiopathic Pulmonary Fibrosis. , 2019, American journal of respiratory and critical care medicine.

[20]  Raúl San José Estépar,et al.  Association Between Interstitial Lung Abnormalities and All-Cause Mortality. , 2016, JAMA.

[21]  Jonathan H. Chung,et al.  Underreporting of Interstitial Lung Abnormalities on Lung Cancer Screening Computed Tomography , 2018, Annals of the American Thoracic Society.

[22]  J. Austin,et al.  High attenuation areas on chest computed tomography in community-dwelling adults: the MESA study , 2016, European Respiratory Journal.

[23]  G. Raghu,et al.  Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. , 2019, The New England journal of medicine.

[24]  R. Munden,et al.  Screening for Lung Cancer: Lexicon for Communicating With Health Care Providers. , 2017, AJR. American journal of roentgenology.

[25]  Katherine Spinks,et al.  The diagnosis and management of interstitial lung diseases , 2015, BMJ : British Medical Journal.

[26]  D. Lynch,et al.  Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. , 2020, The Lancet. Respiratory medicine.

[27]  E. Hoffman,et al.  Air pollution and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis (MESA) air–lung study , 2017, European Respiratory Journal.

[28]  S. Walsh,et al.  Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. , 2019, The New England journal of medicine.

[29]  Edwin J R van Beek,et al.  Cigarette smoking is associated with subclinical parenchymal lung disease: the Multi-Ethnic Study of Atherosclerosis (MESA)-lung study. , 2009, American journal of respiratory and critical care medicine.

[30]  G. Hunninghake.  A new hope for idiopathic pulmonary fibrosis. , 2014, The New England journal of medicine.

[31]  I. Higginson,et al.  Definition, categorization, and terminology of episodic breathlessness: consensus by an international Delphi survey. , 2014, Journal of pain and symptom management.

[32]  D. Lynch,et al.  Computed tomographic findings in subjects who died from respiratory disease in the National Lung Screening Trial , 2017, European Respiratory Journal.

[33]  T. Maher,et al.  Development of a Consensus Statement for the Definition, Diagnosis, and Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis Using the Delphi Technique , 2015, Advances in Therapy.

[34]  Jong Sun Park,et al.  Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases , 2018, European Respiratory Review.

[35]  E. Hoffman,et al.  Occupational Exposures and Subclinical Interstitial Lung Disease. The MESA (Multi‐Ethnic Study of Atherosclerosis) Air and Lung Studies , 2017, American journal of respiratory and critical care medicine.

[36]  Jong Sun Park,et al.  Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. , 2019, The Lancet. Respiratory medicine.

[37]  S. Kudoh,et al.  Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan. , 2015, Respiratory investigation.

[38]  Wenbo Tang,et al.  Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume , 2016, Thorax.

[39]  C. la Vecchia,et al.  Interstitial lung diseases in a lung cancer screening trial , 2011, European Respiratory Journal.

[40]  M. Reiter,et al.  Frequency and distribution of incidental findings deemed appropriate for S modifier designation on low-dose CT in a lung cancer screening program. , 2018, Lung cancer.

[41]  H. Hatabu,et al.  Interstitial Lung Abnormalities Are Associated with Acute Respiratory Distress Syndrome , 2017, American journal of respiratory and critical care medicine.

[42]  G. Hunninghake.  Interstitial lung abnormalities: erecting fences in the path towards advanced pulmonary fibrosis , 2019, Thorax.